A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer

Hou, Xueying; Zhang, Yuelin; Han, Sang Mi; Hou, Baoxian

doi:10.1080/14737140.2020.1838280

Cited by 5 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The upregulated mRNA expression of MYBL2 is positively correlated with high T stage, high Gleason score, worse primary therapy outcome and worse PFI, which was broadly in agreement with previous studies. 25 , 36 , 37 In light of Kaplan-Meier curves and univariate Cox regression analysis, we confirmed that high mRNA expression of MYBL2 is associated with shorter PFI. ROC curve analysis and multivariate Cox proportional hazards analysis indicated that MYBL2 could be a promising diagnostic biomarker to differentiate PCa from normal tissues in early stages of PCa and be used as an independent biomarker of poor prognosis for PCa.…”

Section: Discussionsupporting

confidence: 60%

MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer

Zhang

Teng

et al. 2022

IJGM

View full text Add to dashboard Cite

Purpose MYB proto-oncogene like 2 (MYBL2) is a member of the MYB family of transcription factor genes and overexpressed in many cancers. We investigated the role of MYBL2 in the malignant progression of prostate cancer (PCa) and its relationship with immune infiltrates in PCa. Methods Gene expression level, clinicopathological parameters, Gene Ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway, tumor immune infiltration analysis were based on The Cancer Genome Atlas (TCGA) dataset. Gene set enrichment analysis (GSEA) and single-sample gene set enrichment analysis (ssGSEA) were conducted to analyze the correlation between MYBL2 and immune infiltrates. The data processing analysis based on R language. The relationship between MYBL2 expression and immune response in PCa was analyzed on TIMER 2.0. Results MYBL2 was overexpressed in PCa patients, and correlated with T-stage, Gleason score, primary therapy outcome and progress free interval (PFI) event. The multivariate Cox regression analysis revealed MYBL2 was an independent risk factor for PFI (HR=1.250, 95% CI=1.016–1.537, p=0.035). The receiver operating characteristic (ROC) curve for MYBL2 (AUC=0.887) and nomogram also confirmed the diagnostic value of MYBL2 in the treatment of PCa patients. Based on mRNA expression of MYBL2, PCa patients were divided into MYBL2-high group and MYBL2-low group, and analysis of MYBL2 associated KEGG and GO pathways using R language revealed that 6 immune-related signaling pathways were enriched in MYBL2-high expression phenotype. GSEA analysis showed that 3 hallmark gene sets related to immune response were significantly enriched in MYBL2-high group, ssGSEA analysis found that MYBL2 expression correlated with the expression of many tumor immune lymphocytes (CD8+T cells, neutrophil cells, macrophage cells and so on) and immune check point inhibitors (CD276, BTLA, TNFRSF18, HAVCR2 and CD70). Conclusion MYBL2 is a novel independent prognostic biomarker and MYBL2 may play a crucial role in tumor immune microenvironment of PCa.

show abstract

Section: Discussionsupporting

confidence: 60%

MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer

Zhang

Teng

et al. 2022

IJGM

View full text Add to dashboard Cite

show abstract

“…Previous similar study reported a 10-DNA methylation signature which showed better accuracy in predicting disease-free survival of PCa, including cg02801786, cg00516513, cg21938261, cg06945936, cg08814105, cg20081453, cg22583065, cg01139508, cg25741646 and cg23258881. [ 24 ] These methylation sites were projected into 11 genes (KIF20A, SPAG5, FOXM1, CDCA5, TPX2, PLK1, PRC1, KIF4A, CDKN3, UBE2C, and MYBL2), which were demonstrated to promote the progress of PCa, except for CDCA5 and MYBL2. Obviously, there was no overlapped sites between our findings and the 10-DNA methylation sites.…”

Section: Discussionmentioning

confidence: 99%

Construction of DNA methylation-based nomogram for predicting biochemical-recurrence-free survival in prostate cancer

Zhu

Zhang

2022

Medicine

View full text Add to dashboard Cite

This study aimed to develop a DNA methylation-based nomogram for predicting biochemical recurrence in patients with prostate cancer. A DNA methylation signature was obtained via univariate, lasso, and stepwise multivariate Cox regression models. A 11-DNA methylation signature yielded a high evaluative performance for biochemical-recurrence-free survival. Cox regression analysis indicated that 11-DNA methylation signature and Gleason score served as independent risk factors. A nomogram was constructed based on the 11-DNA methylation signature and Gleason score, and C-index as well as the calibration plots demonstrated good performance and clinical application of the nomogram. A DNA methylation-associated nomogram serve as a prognosis stratification tool to predict the biochemical recurrence of prostate cancer patients after radical prostatectomy.Abbreviations: BCR = biochemical recurrence, BRFS = biochemical recurrence-free survival, K-M = Kaplan-Meier, MAPK8 = mitogen-activated protein kinase 8, NA = not available, PCa = prostate cancer, PHF17 = plant homeodomain protein Jade-1, RP = radical prostatectomy.

show abstract

“…Meanwhile, survival analysis showed that hypermethylation of TFDP2, RBL1, and MYBL2 was associated with poor survival in most cancers. A new DNA methylation 10-CPG disease-free survival prognosis shows that MYBL2 is associated with a high risk of prostate cancer ( Hou et al, 2020 ). Homomorphic diffuse gliomas occur in children and adults and have concise morphologies with frequent MYBL1 and MYB changes and specific DNA methylation features ( Wefers et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of the Expression and Prognosis for the DREAM Complex in Human Cancers

Wang

Liu

2022

Front. Genet.

View full text Add to dashboard Cite

The DREAM complex is an evolutionarily conserved cell cycle regulating multi-protein complex. In addition to playing an essential function in the cell cycle, it also plays a vital role in various survival activities. Accumulating evidence suggests that the DREAM complex plays a crucial role in oncogenesis. However, the regulatory mechanism of the DREAM complex in cancer remains unclear. This study used multi-omics data from Cancer Genome Atlas and Cancer Cell Line Encyclopedia to comprehensively identify the DREAM complex in tumor samples from 33 cancer types. In the genomic landscape, we identified the missense mutation as the dominant alteration events. Expression analysis showed that the expression of methylation-mediated the DREAM complex was downregulated. In addition, we found that the expression of the DREAM complex can be performed to predict the survival of various cancer patients. Pathway activation analysis showed that the DREAM complex is related to apoptosis inhibition, cell cycle, DNA damage response, RAS/MAPK, and RTK signaling pathway activation. Importantly, through a comprehensive analysis of drug sensitivity genomics in cancer databases, we identified a number of potential drugs that may target the DREAM complex. In summary, this study revealed the genomic changes and clinical features of the DREAM complex in 33 cancers, which may also provide new insights for cancer treatment and may offer alternative options for the treatment of clinically refractory cancers.

show abstract

A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer

Cited by 5 publications

References 44 publications

MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer

MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer

Construction of DNA methylation-based nomogram for predicting biochemical-recurrence-free survival in prostate cancer

Comprehensive Analysis of the Expression and Prognosis for the DREAM Complex in Human Cancers

Contact Info

Product

Resources

About